News | September 06, 2021
CRAMS to drive growth for Indian pharma industry: report
The global CRAMS segment is expected to clock 6.2% CAGR over CY21-26E to touch US $ 170 billion
The global CRAMS segment is expected to clock 6.2% CAGR over CY21-26E to touch US $ 170 billion
The drug has been granted permission by DCGI for emergency use as an adjunct therapy for Covid-19
The clinical trial will evaluate the safety, tolerability and pharmacokinetic properties of ICP-723 in patients with solid tumours, and evaluate the anti-tumour efficacy of ICP-723 on NTRK fusion-positive cancers
The drug is also intended for the treatment of glioblastoma multiforme
The value of the contract is estimated to be between Rs 20-30 crores per year for the next three years
Acetaminophen extended-release tablets 650 mg is bioequivalent of the reference listed drug Tylenol
The two-year donation supports the development of clinical tests for Covid-19 severity assessment and the focus on the development of simple immunoassays using single molecule counting technology
Opaganib, a leading novel small molecule investigational oral pill in development for Covid-19, is a unique host targeted, dual antiviral and anti-inflammatory drug that acts on the cause and effect of the disease
First results demonstrate favourable tolerability of TQL-1055 at all dose levels
Domestic business was up 41.9% YoY and 27.7% QoQ
Subscribe To Our Newsletter & Stay Updated
